Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.43 |
| ▸ | KDM1A | O60341 | 4/20 | 0.37 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3323591 | 1.00 | TRPV1 (0.43) | TRPV1KDM1AKDM1BKCNH2DRD2 | |
| SCHEMBL3322340 | 1.00 | TRPV1 (0.43) | TRPV1KDM1AKDM1BKCNH2DRD2 | |
| Ammonia Solution, Strong SCHEMBL13685415 | 0.98 | TRPV1 (0.42) | TRPV1KDM1AKDM1BKCNH2DRD2 | |
| Hydrochloric Acid SCHEMBL6558690 | 0.95 | TRPV1 (0.40) | TRPV1KDM1AKDM1BKCNH2HTR2A | |
| Hydrochloric Acid SCHEMBL6559908 | 0.94 | TRPV1 (0.39) | TRPV1KDM1AKDM1BKCNH2 | |
| SCHEMBL619207 | 0.88 | TRPV1 (0.37) | TRPV1KDM1ADRD2HTR2A | |
| SCHEMBL4355338 | 0.84 | KDM1A (0.36) | TRPV1KDM1ADRD2HTR2A | |
| SCHEMBL23408936 | 0.82 | TRPV1 (0.45) | TRPV1HTR2A | |
| SCHEMBL619899 | 0.82 | KDM4E (0.41) | TRPV1 | |
| SCHEMBL3804677 | 0.82 | TRPV3 (0.38) | KDM1AKCNH2DRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859584-B2 | TRPV1 antagonists | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| WO-2013096223-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158067-A1 | TRPV1 Antagonists | ABBVIE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-1931681-B1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS SA (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-20120277259-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-12-09 | — | — | US | disclosed |
| US-7842703-B2 | Substituted benzofused derivatives and their use as vanilloid receptor ligands | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-11-30 | — | — | US | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045401-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009084034-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S. A. (CH) | 2009-07-09 | — | — | WO | disclosed |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | ABBOTT GMBH & CO. KG (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20080269253-A1 | Substituted Benzofused Derivatives and Their Use as Vanilloid Receptor Ligands | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1931681-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | Glenmark Pharmaceuticals S.A. (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007042906-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | TRPV3, TRPV2, TRPV1 | TRPV1 3/4885KDM1A 3314/4885KDM1B 3628/4885 |
| US-20080269253-A1 | Substituted Benzofused Derivatives and Their Use as Vanilloid Receptor Ligands | TRPV1, GPR17, TRPV6 | TRPV1 1/4885KDM1A 3486/4885KDM1B 3087/4885 |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885KDM1A 3338/4885KDM1B 3558/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885KDM1A 3414/4885KDM1B 3679/4885 |
| US-20130158067-A1 | TRPV1 Antagonists | TRPV1, NPY1R, MRGPRX1 | TRPV1 1/4885KDM1A 2692/4885KDM1B 2687/4885 |
| US-20120277259-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | TRPV1 1/4885KDM1A 3486/4885KDM1B 3087/4885 |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | U2SURP, UMPS, HNRNPUL1 | TRPV1 4781/4885KDM1A 582/4885KDM1B 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.